Levothyroxine (Euthyrox) Dosing and Timing
Take levothyroxine 1.6 mcg/kg/day as a single morning dose on an empty stomach, at least 30-60 minutes before breakfast, for optimal absorption and therapeutic efficacy. 1
Standard Dosing Guidelines
Initial Dosing for Adults
- For adults under 70 years without cardiac disease: Start with the full replacement dose of 1.6 mcg/kg/day 2, 1
- For adults over 70 years or with cardiac disease: Start with a lower dose of 25-50 mcg/day and titrate gradually every 6-8 weeks to avoid cardiac complications 2, 1
- For patients at risk of atrial fibrillation: Use a lower starting dose and slower titration to prevent exacerbation of cardiac symptoms 1
Dose Adjustments
- Increase levothyroxine by 12.5-25 mcg increments every 4-6 weeks based on TSH and free T4 levels until the patient is euthyroid 2, 1
- Target TSH range: 0.5-4.5 mIU/L with normal free T4 for primary hypothyroidism 2
- Monitor TSH every 6-8 weeks during dose titration, as it takes 4-6 weeks to reach steady state after any dose change 2, 1
- Once stable: Recheck TSH every 6-12 months or if symptoms change 2
Optimal Timing for Administration
Morning Administration (Standard Recommendation)
- Take levothyroxine 30-60 minutes before breakfast on an empty stomach for maximum absorption 1, 3
- This timing ensures optimal gastric acidity and minimal food interference with absorption 3
- Taking levothyroxine with food significantly reduces its bioavailability 4
Alternative Timing Options
- Bedtime administration (at least 1 hour after dinner) results in lower TSH levels (decrease of 1.25 mIU/L), higher free T4 (increase of 0.07 ng/dL), and higher total T3 (increase of 6.5 ng/dL) compared to morning dosing 5
- Bedtime dosing may improve thyroid hormone levels but shows no difference in quality of life measures 5
- Switching from morning to evening administration reduces therapeutic efficacy, with TSH increasing by 1.47 µIU/mL and T4 decreasing by 0.35 µg/dL 4
Critical Timing Considerations
- Avoid taking levothyroxine with food, coffee, or other medications as these significantly impair absorption 3
- Separate levothyroxine from other medications by at least 4 hours when possible, particularly calcium, iron, proton pump inhibitors, and antacids 1
- Liquid levothyroxine formulations may allow for administration closer to meals (15-30 minutes before) with maintained bioavailability, though this is not standard practice 6, 7
Special Population Dosing
Pregnant Patients
- Increase levothyroxine dose by 25-50% as soon as pregnancy is confirmed, as requirements increase during early pregnancy 2, 1
- Monitor TSH every 4 weeks during pregnancy and maintain TSH within trimester-specific reference ranges 1
- Return to pre-pregnancy dose immediately after delivery and recheck TSH 4-8 weeks postpartum 1
Pediatric Patients
- Dosing is weight-based and age-dependent: 10-15 mcg/kg/day for infants 0-3 months, decreasing to 1.6 mcg/kg/day once growth and puberty are complete 1
- Titrate every 2 weeks in pediatric patients based on TSH and free T4 until euthyroid 1
Thyroid Cancer Patients
- TSH suppression targets vary by risk stratification: TSH 0.5-2 mIU/L for low-risk patients, 0.1-0.5 mIU/L for intermediate-risk, and <0.1 mIU/L for high-risk or structural incomplete response 2
- These patients require endocrinologist consultation for target TSH determination 2
Common Pitfalls to Avoid
- Never start levothyroxine before ruling out adrenal insufficiency in patients with suspected central hypothyroidism, as this can precipitate life-threatening adrenal crisis 2
- Avoid treating based on a single elevated TSH value without confirmation, as 30-60% of elevated TSH levels normalize spontaneously 2
- Do not adjust doses more frequently than every 4-6 weeks, as steady state is not reached before this time 2, 1
- Approximately 25% of patients are unintentionally overtreated with TSH suppression, increasing risks for atrial fibrillation, osteoporosis, and cardiac complications 2
- Taking levothyroxine inconsistently or with food is the most common cause of inadequate response to therapy 1, 3